Study on Working Memory in Adolescents with Autism in the Netherlands (amendment regarding an extension using fMRI)
- Conditions
- High functioning Autism10012562
- Registration Number
- NL-OMON38231
- Lead Sponsor
- Epilepsiecentrum Kempenhaeghe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 276
For adolescents with HFA:
- Age of 12 to 16 years.
- Autism disorder or Asperger disorder diagnosis made conform the diagnosis criteria as formulated in the DSM-IV.
- A signed informed consent (IC) from the adolescent and the parent/ caregiver.
- A high average intelligence conform a HAVO/VWO education level.;For normal control adolescents:;- Age of 12 to 16 years
- A signed IC from the adolescent and the parent/ caregiver.
- A high average intelligence conform a HAVO/VWO education level.
For adolescents with HFA:
- A diagnosis for other (co-morbid) psychological disorders or psychiatric diseases as formulated in the DSM-IV, such as: attention-deficit and disruptive behaviour disorders, anxiety disorders and mood disorders.
- Appearance of additional variables that can influence cognitive functioning such as pathology of the Central Nervous System (CNS), significant hearing impairment, and medicinal treatment for epilepsy.
- Use of Methylphenidate. In consultation with the responsible doctor, parent/caregiver and adolescent are asked if they are willing to not take the medicine on the day of the neuropsychological assessment. If all agree, the adolescent may participate in the study.
- Inability to speak/understand the Dutch language.
- Vision less than +4.5D or - 4.5D.
• Claustrophobia.
• Metal implants or other contraindication for MRI.;For normal control adolescents:
- A diagnosis for a psychological disorder or psychiatric disease as formulated in the DSM-IV, such as: pervasive developmental disorders, attention-deficit and disruptive behaviour disorders, separation anxiety disorders, selective mutism, reactive attachment disorder of infancy or early childhood, anxiety disorders and mood disorders.
- Appearance of additional variables that can influence cognitive functioning such as pathology of the CNS, significant hearing impairment, and medicinal treatment for epilepsy.
- Use of Methylphenidate. In consultation with the responsible doctor, parent/caregiver and adolescent are asked if they are willing not to take the medicine on the day of the neuropsychological assessment. If all agree, the adolescent may participate in the study.
- Inability to speak/understand the Dutch language.
- Vision less than +4.5D or - 4.5D.
• Claustrophobia.
• Metal implants or other contraindication for MRI.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method